|
시장보고서
상품코드
2024755
리포솜 독소루비신 시장 분석 : 제품별, 용도별, 지역별(2026-2034년)Liposomal Doxorubicin Market Report by Product (Doxil/Caelyx, Lipodox, Myocet, and Others), Application (Leukemia, Bone Sarcoma, Breast Cancer, Endometrial Cancer, Kidney Cancer, Multiple Myeloma, Kaposi Sarcoma, and Others), and Region 2026-2034 |
||||||
세계의 리포솜 독소루비신 시장 규모는 2025년에 14억 달러에 이르렀습니다. 향후, IMARC Group은 2034년까지 시장 규모가 21억 달러에 이르고, 2026-2034년 CAGR 4.53%를 나타낼 것으로 예측했습니다.
리포솜 독소루비신은 다양한 자가면역질환과 간암, 유방암, 자궁내막암, 위암, 신장암 치료에 사용되는 화학요법제입니다. 체내 암세포의 증식을 억제하거나 지연시키는 작용을 합니다. 이 약제는 페그화 리포솜이라는 지질막으로 싸여 있으며, 주사를 통해 정맥으로 투여합니다. 독소루비신은 암세포가 분열, 증식하는 데 필요한 효소를 억제하고, 리포솜은 약물이 혈류에 더 오래 머물러 암세포에 도달하여 효과를 높이는 역할을 합니다. 복용량은 환자의 체중, 신장, 전신 상태에 따라 달라집니다. 리포솜 독소루비신은 기존에 사용되던 약물과 비교하여 독성, 골수 억제, 탈모 및 메스꺼움이 적다는 특징이 있습니다.
리포솜 독소루비신 시장 동향 :
골육종, 다발성 골수종, 난소암, 후천성면역결핍증후군(AIDS) 관련 카포시 육종과 같은 만성 질환의 유병률이 전 세계적으로 증가하고 있는 것이 시장 성장을 이끄는 주요 요인 중 하나입니다. 이는 대다수 노동 인구의 좌식 생활 습관과 바쁜 일정으로 인해 이러한 질병의 발생률이 크게 증가하여 리포솜 독소루비신 제제에 대한 수요에 긍정적인 영향을 미치고 있습니다. 또한, 암에 대한 치료 옵션에 대한 대중의 인식이 높아지면서 시장 성장을 가속하고 있습니다. 획기적인 나노 의약품의 개발, 화학요법제의 개선 등 다양한 발전도 시장 성장을 가속하는 요인으로 작용하고 있습니다. 이러한 혁신을 통해 체내 특정 부위에 약물을 전달하고 약물을 제어된 상태로 방출할 수 있습니다. 또한, 특히 개발도상국의 의료 인프라가 크게 개선되고, 종양학 분야의 광범위한 연구개발(R&D) 활동 등이 시장 성장을 견인할 것으로 예측됩니다.
본 보고서에서 답변을 얻을 수 있는 주요 질문
- 지금까지 세계 리포솜 독소루비신 시장은 어떻게 성장해 왔으며, 향후 몇 년 동안 어떻게 성장할 것인가?
- COVID-19는 세계 리포솜 독소루비신 시장에 어떤 영향을 미쳤을까?
- 주요 지역 시장은 어디인가?
- 제품별로 보면, 시장은 어떻게 구분되는가?
- 용도별 시장 현황은?
- 이 산업의 가치사슬의 각 단계는 어떤 것인가?
- 이 산업의 주요 촉진요인과 과제는?
- 세계 리포솜 독소루비신 시장의 구조는 무엇이며, 주요 기업은?
- 업계의 경쟁은 어느 정도인가?
목차
제1장 서문
제2장 분석 범위 및 방법
제3장 주요 요약
제4장 서론
제5장 세계의 리포솜 독소루비신 시장
제6장 시장 구분 : 제품별
제7장 시장 구분 : 용도별
제8장 시장 구분 : 지역별
제9장 SWOT 분석
제10장 밸류체인 분석
제11장 Porter's Five Forces 분석
제12장 가격 분석
제13장 경쟁 구도
JHS 26.05.20The global liposomal doxorubicin market size reached USD 1.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 2.1 Billion by 2034, exhibiting a growth rate (CAGR) of 4.53% during 2026-2034.
Liposomal doxorubicin is a chemotherapy drug used for the treatment of various autoimmune disorders and cancer of the liver, breast, endometrial, gastric and kidney. It functions by stopping or slowing cancer cell growth in the body. The medication is wrapped in a fatty covering of pegylated liposome and is administered intravenously through an injection. The doxorubicin drug blocks the enzymes required by cancer cells to divide and grow and the liposomes ensure that the drug stays in the bloodstream longer and reaches the cancer cells for enhanced efficacy. The dosage of the medication varies on the weight, height and general health of the patient. In comparison to the traditionally used drugs, liposome doxorubicin exhibits lesser toxicity, myelosuppression, alopecia and nausea.
LIPOSOMAL DOXORUBICIN MARKET TRENDS:
The increasing prevalence of chronic medical ailments, such as bone sarcoma, multiple myeloma, ovarian cancer and Autoimmune Deficiency Syndrome (AIDS)-related Kaposi sarcoma, across the globe is one of the key factors driving the market growth. This can be attributed to the sedentary lifestyles and hectic schedules of a majority of the working population, which, in turn, is significantly increasing the occurrence of these disorders and positively impacting the demand for liposomal doxorubicin drugs. Moreover, rising awareness among the masses regarding the available treatment alternatives for cancer is providing a thrust to the growth of the market. Various advancements, such as the development of paradigmatic nanodrugs and improved chemotherapeutic agents, are acting as other growth-inducing factors. These innovations facilitate site-specific delivery and controlled release of the drug in the body. Other factors, including significant improvements in the healthcare infrastructure, especially of the developing economies, along with extensive research and development (R&D) activities in the field of oncology, are anticipated to drive the market toward growth.
KEY MARKET SEGMENTATION:
Breakup by Product:
- Doxil/Caelyx
- Lipodox
- Myocet
- Others
Breakup by Application:
- Leukemia
- Bone Sarcoma
- Breast Cancer
- Endometrial Cancer
- Kidney Cancer
- Multiple Myeloma
- Kaposi Sarcoma
- Others
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
COMPETITIVE LANDSCAPE:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Cipla Inc., Johnson & Johnson, Merck KGaA, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, TTY Biopharm Company Limited and Zydus Cadila.
KEY QUESTIONS ANSWERED IN THIS REPORT
- How has the global liposomal doxorubicin market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global liposomal doxorubicin market?
- What are the key regional markets?
- What is the breakup of the market based on the product?
- What is the breakup of the market based on the application?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global liposomal doxorubicin market and who are the key players?
- What is the degree of competition in the industry?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Liposomal Doxorubicin Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product
- 6.1 Doxil/Caelyx
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Lipodox
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Myocet
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
- 6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast
7 Market Breakup by Application
- 7.1 Leukemia
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Bone Sarcoma
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Breast Cancer
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Endometrial Cancer
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Kidney Cancer
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Multiple Myeloma
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
- 7.7 Kaposi Sarcoma
- 7.7.1 Market Trends
- 7.7.2 Market Forecast
- 7.8 Others
- 7.8.1 Market Trends
- 7.8.2 Market Forecast
8 Market Breakup by Region
- 8.1 North America
- 8.1.1 United States
- 8.1.1.1 Market Trends
- 8.1.1.2 Market Forecast
- 8.1.2 Canada
- 8.1.2.1 Market Trends
- 8.1.2.2 Market Forecast
- 8.1.1 United States
- 8.2 Asia-Pacific
- 8.2.1 China
- 8.2.1.1 Market Trends
- 8.2.1.2 Market Forecast
- 8.2.2 Japan
- 8.2.2.1 Market Trends
- 8.2.2.2 Market Forecast
- 8.2.3 India
- 8.2.3.1 Market Trends
- 8.2.3.2 Market Forecast
- 8.2.4 South Korea
- 8.2.4.1 Market Trends
- 8.2.4.2 Market Forecast
- 8.2.5 Australia
- 8.2.5.1 Market Trends
- 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
- 8.2.6.1 Market Trends
- 8.2.6.2 Market Forecast
- 8.2.7 Others
- 8.2.7.1 Market Trends
- 8.2.7.2 Market Forecast
- 8.2.1 China
- 8.3 Europe
- 8.3.1 Germany
- 8.3.1.1 Market Trends
- 8.3.1.2 Market Forecast
- 8.3.2 France
- 8.3.2.1 Market Trends
- 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
- 8.3.3.1 Market Trends
- 8.3.3.2 Market Forecast
- 8.3.4 Italy
- 8.3.4.1 Market Trends
- 8.3.4.2 Market Forecast
- 8.3.5 Spain
- 8.3.5.1 Market Trends
- 8.3.5.2 Market Forecast
- 8.3.6 Russia
- 8.3.6.1 Market Trends
- 8.3.6.2 Market Forecast
- 8.3.7 Others
- 8.3.7.1 Market Trends
- 8.3.7.2 Market Forecast
- 8.3.1 Germany
- 8.4 Latin America
- 8.4.1 Brazil
- 8.4.1.1 Market Trends
- 8.4.1.2 Market Forecast
- 8.4.2 Mexico
- 8.4.2.1 Market Trends
- 8.4.2.2 Market Forecast
- 8.4.3 Others
- 8.4.3.1 Market Trends
- 8.4.3.2 Market Forecast
- 8.4.1 Brazil
- 8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast
9 SWOT Analysis
- 9.1 Overview
- 9.2 Strengths
- 9.3 Weaknesses
- 9.4 Opportunities
- 9.5 Threats
10 Value Chain Analysis
11 Porters Five Forces Analysis
- 11.1 Overview
- 11.2 Bargaining Power of Buyers
- 11.3 Bargaining Power of Suppliers
- 11.4 Degree of Competition
- 11.5 Threat of New Entrants
- 11.6 Threat of Substitutes
12 Price Analysis
13 Competitive Landscape
- 13.1 Market Structure
- 13.2 Key Players
- 13.3 Profiles of Key Players
- 13.3.1 Baxter International Inc.
- 13.3.1.1 Company Overview
- 13.3.1.2 Product Portfolio
- 13.3.1.3 Financials
- 13.3.1.4 SWOT Analysis
- 13.3.2 Cipla Inc.
- 13.3.2.1 Company Overview
- 13.3.2.2 Product Portfolio
- 13.3.2.3 Financials
- 13.3.2.4 SWOT Analysis
- 13.3.3 Johnson & Johnson
- 13.3.3.1 Company Overview
- 13.3.3.2 Product Portfolio
- 13.3.3.3 Financials
- 13.3.3.4 SWOT Analysis
- 13.3.4 Merck KGaA
- 13.3.4.1 Company Overview
- 13.3.4.2 Product Portfolio
- 13.3.4.3 Financials
- 13.3.4.4 SWOT Analysis
- 13.3.5 Pfizer Inc.
- 13.3.5.1 Company Overview
- 13.3.5.2 Product Portfolio
- 13.3.5.3 Financials
- 13.3.5.4 SWOT Analysis
- 13.3.6 Sun Pharmaceutical Industries Ltd
- 13.3.6.1 Company Overview
- 13.3.6.2 Product Portfolio
- 13.3.6.3 Financials
- 13.3.6.4 SWOT Analysis
- 13.3.7 Teva Pharmaceutical Industries Ltd
- 13.3.7.1 Company Overview
- 13.3.7.2 Product Portfolio
- 13.3.7.3 Financials
- 13.3.7.4 SWOT Analysis
- 13.3.8 TTY Biopharm Company Limited
- 13.3.8.1 Company Overview
- 13.3.8.2 Product Portfolio
- 13.3.8.3 Financials
- 13.3.9 Zydus Cadila
- 13.3.9.1 Company Overview
- 13.3.9.2 Product Portfolio
- 13.3.1 Baxter International Inc.
